ReviewViruses2013
RSV fusion: time for a new model.
Review in Viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Respiratory syncytial virus fuses with plasma membrane to infect primary cultures of bronchial epithelial cells.Frontiers in microbiology · 2025Article
- Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus.Pathogens (Basel, Switzerland) · 2023Review
- Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children.Virus genes · 2022Review
- Immunoinformatics-Aided Analysis of RSV Fusion and Attachment Glycoproteins to Design a Potent Multi-Epitope Vaccine.Vaccines · 2022Article
- Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses.PPAR research · 2021Review
- Innate Immune Components that Regulate the Pathogenesis and Resolution of hRSV and hMPV Infections.Viruses · 2020Review
- Multiepitope-Based Subunit Vaccine Design and Evaluation against Respiratory Syncytial Virus Using Reverse Vaccinology Approach.Vaccines · 2020Article
- Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.Viruses · 2020Review
- Syncytia Formation in Oncolytic Virotherapy.Molecular therapy oncolytics · 2019Review
- Host Components Contributing to Respiratory Syncytial Virus Pathogenesis.Frontiers in immunology · 2019Review
- Annexin A2 in Virus Infection.Frontiers in microbiology · 2018Article
- Article
- Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection.Virology journal · 2017Article
- New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.International journal of molecular sciences · 2017Review
- Article
- Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.International journal of molecular sciences · 2017Review
- Human Respiratory Syncytial Virus: Infection and Pathology.Seminars in respiratory and critical care medicine · 2016Review
- Exposure to common respiratory bacteria alters the airway epithelial response to subsequent viral infection.Respiratory research · 2016Article
- Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.The Journal of general virology · 2015Article
- Challenges and opportunities in developing respiratory syncytial virus therapeutics.The Journal of infectious diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review we propose a partially hypothetical model of respiratory syncytial virus (RSV) binding and entry to the cell that includes the recently discovered RSV receptor nucleolin, in an attempt to stimulate further inquiry in this research area. RSV binding and entry is likely to be a two-step process, the first involving the attachment of the virus to the cell membrane, which may be enhanced by electrostatic interactions with cellular glycoproteins/heparin and the viral G protein, and the second involving fusion to the cell membrane mediated by the viral F protein and a specific cellular fusion receptor. With our recent discovery of nucleolin as a functional fusion receptor for RSV, comes the possibility of a number of new approaches to the development of novel strategies for RSV prophylaxis and therapy, as well as raising some new questions concerning the pathobiology of RSV infection and tropism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.